• STAT+: Editas, facing another setback, halts development on first clinical CRISPR program

    16 days ago - By STAT

    Editas Medicine, one of the small handful of original CRISPR companies, announced Thursday it is halting development on its first clinical program after data showed only a small subset of patients were responding.
    Edit-101, an experimental CRISPR-based treatment for a rare eye disease called CEP290-meditated LCA10, led to “clinically meaningful” improvements in sight in only three out of 14 patients treated in the company's Phase I study. Continue to STAT+ to read the full story...
    Read more ...